401 related articles for article (PubMed ID: 10385319)
1. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices.
Sturniolo T; Bono E; Ding J; Raddrizzani L; Tuereci O; Sahin U; Braxenthaler M; Gallazzi F; Protti MP; Sinigaglia F; Hammer J
Nat Biotechnol; 1999 Jun; 17(6):555-61. PubMed ID: 10385319
[TBL] [Abstract][Full Text] [Related]
2. HLA-DR restrictive supertypes dominate promiscuous T cell recognition: association of multiple HLA-DR molecules with susceptibility to autoimmune diseases.
Ou D; Mitchell LA; Tingle AJ
J Rheumatol; 1997 Feb; 24(2):253-61. PubMed ID: 9034980
[TBL] [Abstract][Full Text] [Related]
3. In silico binding predictions for identification of HLA-DR-promiscuous regions and epitopes of Mycobacterium tuberculosis protein MPT64 (Rv1980c) and their recognition by human Th1 cells.
Mustafa AS
Med Princ Pract; 2010; 19(5):367-72. PubMed ID: 20639660
[TBL] [Abstract][Full Text] [Related]
4. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
5. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands.
Marshall KW; Liu AF; Canales J; Perahia B; Jorgensen B; Gantzos RD; Aguilar B; Devaux B; Rothbard JB
J Immunol; 1994 May; 152(10):4946-57. PubMed ID: 8176213
[TBL] [Abstract][Full Text] [Related]
6. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
Daubenberger CA; Nickel B; Ciatto C; Grütter MG; Pöltl-Frank F; Rossi L; Siegler U; Robinson J; Kashala O; Patarroyo ME; Pluschke G
Eur J Immunol; 2002 Dec; 32(12):3667-77. PubMed ID: 12516559
[TBL] [Abstract][Full Text] [Related]
7. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
[TBL] [Abstract][Full Text] [Related]
8. Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens.
Marrari M; Duquesnoy RJ
Tissue Antigens; 2009 Aug; 74(2):134-46. PubMed ID: 19497040
[TBL] [Abstract][Full Text] [Related]
9. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
10. Class II HLA-peptide binding prediction using structural principles.
Mohanapriya A; Lulu S; Kayathri R; Kangueane P
Hum Immunol; 2009 Mar; 70(3):159-69. PubMed ID: 19187794
[TBL] [Abstract][Full Text] [Related]
11. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming.
Kropshofer H; Max H; Halder T; Kalbus M; Muller CA; Kalbacher H
J Immunol; 1993 Nov; 151(9):4732-42. PubMed ID: 8409432
[TBL] [Abstract][Full Text] [Related]
12. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
[TBL] [Abstract][Full Text] [Related]
13. T-cell epitopes of the La/SSB autoantigen: prediction based on the homology modeling of HLA-DQ2/DQ7 with the insulin-B peptide/HLA-DQ8 complex.
Kosmopoulou A; Vlassi M; Stavrakoudis A; Sakarellos C; Sakarellos-Daitsiotis M
J Comput Chem; 2006 Jul; 27(9):1033-44. PubMed ID: 16639700
[TBL] [Abstract][Full Text] [Related]
14. HLA and leprosy in the pre and postgenomic eras.
Geluk A; Ottenhoff TH
Hum Immunol; 2006 Jun; 67(6):439-45. PubMed ID: 16728267
[TBL] [Abstract][Full Text] [Related]
15. TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules.
Zhang L; Chen Y; Wong HS; Zhou S; Mamitsuka H; Zhu S
PLoS One; 2012; 7(2):e30483. PubMed ID: 22383964
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1.
Bastian M; Lozano JM; Patarroyo ME; Pluschke G; Daubenberger CA
Mol Immunol; 2004 Jul; 41(8):775-84. PubMed ID: 15234557
[TBL] [Abstract][Full Text] [Related]
17. Th1 cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis.
Mustafa AS
Scand J Immunol; 2009 Mar; 69(3):213-22. PubMed ID: 19281533
[TBL] [Abstract][Full Text] [Related]
18. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
19. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
Sun Y; Song M; Jäger E; Schwer C; Stevanovic S; Flindt S; Karbach J; Nguyen XD; Schadendorf D; Cichutek K
Clin Cancer Res; 2008 Jul; 14(13):4306-15. PubMed ID: 18594014
[TBL] [Abstract][Full Text] [Related]
20. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE.
Bian H; Hammer J
Methods; 2004 Dec; 34(4):468-75. PubMed ID: 15542373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
